Literature DB >> 12875962

Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants.

Rafia S Al-Lamki1, Jun Wang, Sathia Thiru, Nicholas R Pritchard, J Andrew Bradley, Jordan S Pober, John R Bradley.   

Abstract

We have previously reported the pattern of cellular expression of tumor necrosis factor receptors (TNFR) in human kidney and their altered expression in transplant rejection. We have extended our studies to examine the expression of Silencer of Death Domains (SODD), a protein that binds to the cytoplasmic portion of TNFR1 to inhibit signaling in the absence of ligand. In normal human kidney SODD is expressed in glomerular endothelial cells where it colocalizes with TNFR1. During acute rejection both SODD and TNFR1 are lost from glomeruli, but we found strong expression of SODD on the luminal surface of tubular epithelial cells. This occurs in the absence of detectable TNFR1 expression, suggesting that SODD could interact with other proteins at these sites. Several other members of the TNF superfamily, including Fas and death receptors (DR)-3, -4, and -5, also contain intracellular death domains, but SODD only interacts with the death domain of DR3. We therefore studied the expression of DR3 in human kidney, and report that this death receptor is up-regulated in renal tubular epithelial cells and endothelial cells of some interlobular arteries, in parallel with SODD, during acute transplant rejection. In less severe rejection episodes, DR3 and SODD were more focally induced, generally at sites of mononuclear cell infiltrates. In ischemic allografts, eg, with acute tubular necrosis but no cellular rejection, DR3 was induced on tubular epithelial cells and on glomerular endothelial cells. These data confirm that TNF receptor family members are expressed in a regulated manner during renal transplant rejection, and identify DR3 as a potential inducible mediator of tubular inflammation and injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875962      PMCID: PMC1868232          DOI: 10.1016/S0002-9440(10)63670-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3).

Authors:  A Kaptein; M Jansen; G Dilaver; J Kitson; L Dash; E Wang; M J Owen; J L Bodmer; J Tschopp; S N Farrow
Journal:  FEBS Lett       Date:  2000-11-24       Impact factor: 4.124

2.  Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system.

Authors:  A Eggert; M A Grotzer; T J Zuzak; N Ikegaki; H Zhao; G M Brodeur
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

3.  Tumor necrosis factor receptor 1 is an ATPase regulated by silencer of death domain.

Authors:  Kiyoshi Miki; Edward M Eddy
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  TR3 death receptor expression in the normal and ischaemic brain.

Authors:  D C Harrison; J Roberts; C A Campbell; B Crook; R Davis; K Deen; J Meakin; D Michalovich; J Price; M Stammers; P R Maycox
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

5.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

Review 6.  The kiss of death: promises and failures of death receptors and ligands in cancer therapy.

Authors:  P T Daniel; T Wieder; I Sturm; K Schulze-Osthoff
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

7.  Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants.

Authors:  R S Al-Lamki; J Wang; J N Skepper; S Thiru; J S Pober; J R Bradley
Journal:  Lab Invest       Date:  2001-11       Impact factor: 5.662

8.  Specific features of apoptosis in human lens epithelial cells induced by mitomycin C in vitro.

Authors:  J F Jordan; N Kociok; S Grisanti; P C Jacobi; J M Esser; T T Luther; G K Krieglstein; P Esser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-08       Impact factor: 3.117

9.  Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells.

Authors:  J R Bradley; S Thiru; J S Pober
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

10.  Prevention of constitutive TNF receptor 1 signaling by silencer of death domains.

Authors:  Y Jiang; J D Woronicz; W Liu; D V Goeddel
Journal:  Science       Date:  1999-01-22       Impact factor: 47.728

View more
  16 in total

Review 1.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

2.  Silencer of death domains (SODD) inhibits skeletal muscle and kidney enriched inositol 5-phosphatase (SKIP) and regulates phosphoinositide 3-kinase (PI3K)/Akt signaling to the actin cytoskeleton.

Authors:  Parvin Rahman; Richard D Huysmans; Fenny Wiradjaja; Rajendra Gurung; Lisa M Ooms; David A Sheffield; Jennifer M Dyson; Meredith J Layton; Absorn Sriratana; Hidetoshi Takada; Tony Tiganis; Christina A Mitchell
Journal:  J Biol Chem       Date:  2011-06-28       Impact factor: 5.157

Review 3.  The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.

Authors:  Arianne C Richard; John R Ferdinand; Françoise Meylan; Erika T Hayes; Odile Gabay; Richard M Siegel
Journal:  J Leukoc Biol       Date:  2015-07-17       Impact factor: 4.962

Review 4.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

5.  TL1A both promotes and protects from renal inflammation and injury.

Authors:  Rafia S Al-Lamki; Jun Wang; Aviva M Tolkovsky; J Andrew Bradley; Jules L Griffin; Sathia Thiru; Eddie C Y Wang; Eleanor Bolton; Wang Min; Paul Moore; Jordan S Pober; John R Bradley
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

6.  TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart disease.

Authors:  Rafia S Al-Lamki; Wanhua Lu; Jun Wang; Jun Yang; Timothy J Sargeant; Richard Wells; Chenqu Suo; Penny Wright; Martin Goddard; Qunhua Huang; Amir H Lebastchi; George Tellides; Yingqun Huang; Wang Min; Jordan S Pober; John R Bradley
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

Review 7.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

Review 8.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

9.  FOXO3a regulates oxygen-responsive expression of tumor necrosis factor receptor 2 in human dermal microvascular endothelial cells.

Authors:  Bo Ding; Nancy C Kirkiles-Smith; Jordan S Pober
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

10.  Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.

Authors:  Imtiyaz Murtaza; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Mohammad Saleem; Hasan Mukhtar
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.